Your browser doesn't support javascript.
loading
Long/post-COVID in children and adolescents: symptom onset and recovery after one year based on healthcare records in Germany.
Ehm, Franz; Tesch, Falko; Menzer, Simone; Loser, Friedrich; Bechmann, Lars; Vivirito, Annika; Wende, Danny; Batram, Manuel; Buschmann, Tilo; Ludwig, Marion; Roessler, Martin; Seifert, Martin; Sarganas Margolis, Giselle; Reitzle, Lukas; Koenig, Christina; Schulte, Claudia; Ballesteros, Pedro; Bassler, Stefan; Bitterer, Thomas; Riederer, Cordula; Berner, Reinhard; Scheidt-Nave, Christa; Schmitt, Jochen; Toepfner, Nicole.
Afiliação
  • Ehm F; Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany. franz.ehm@ukdd.de.
  • Tesch F; Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
  • Menzer S; IKK Classic, Tannenstraße 4 B, 01099, Dresden, Germany.
  • Loser F; Techniker Krankenkasse, Bramfelder Straße 140, 22305, Hamburg, Germany.
  • Bechmann L; IKK Classic, Tannenstraße 4 B, 01099, Dresden, Germany.
  • Vivirito A; InGef - Institute for Applied Health Research Berlin GmbH, Otto-Ostrowski-Straße 5, 10249, Berlin, Germany.
  • Wende D; BARMER Institut für Gesundheitssystemforschung (Bifg), Axel-Springer-Straße 44, 10969, Berlin, Germany.
  • Batram M; Vandage GmbH, Detmolder Str. 30, 33604, Bielefeld, Germany.
  • Buschmann T; AOK PLUS, Sternplatz 7, 01067, Dresden, Germany.
  • Ludwig M; InGef - Institute for Applied Health Research Berlin GmbH, Otto-Ostrowski-Straße 5, 10249, Berlin, Germany.
  • Roessler M; BARMER Institut für Gesundheitssystemforschung (Bifg), Axel-Springer-Straße 44, 10969, Berlin, Germany.
  • Seifert M; Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
  • Sarganas Margolis G; Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany.
  • Reitzle L; Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany.
  • Koenig C; Techniker Krankenkasse, Bramfelder Straße 140, 22305, Hamburg, Germany.
  • Schulte C; BARMER Institut für Gesundheitssystemforschung (Bifg), Axel-Springer-Straße 44, 10969, Berlin, Germany.
  • Ballesteros P; BARMER Institut für Gesundheitssystemforschung (Bifg), Axel-Springer-Straße 44, 10969, Berlin, Germany.
  • Bassler S; AOK PLUS, Sternplatz 7, 01067, Dresden, Germany.
  • Bitterer T; IKK Classic, Tannenstraße 4 B, 01099, Dresden, Germany.
  • Riederer C; DAK-Gesundheit, Nagelsweg 27 - 31, 20097, Hamburg, Germany.
  • Berner R; Department of Pediatrics, University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
  • Scheidt-Nave C; Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany.
  • Schmitt J; Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
  • Toepfner N; Department of Pediatrics, University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
Infection ; 2024 Sep 16.
Article em En | MEDLINE | ID: mdl-39285063
ABSTRACT

PURPOSE:

Evidence on the incidence and persistence of post-acute sequelae of COVID-19 (PASC) among children and adolescents is still limited.

METHODS:

In this retrospective cohort study, 59,339 children and adolescents with laboratory-confirmed COVID-19 in 2020 and 170,940 matched controls were followed until 2021-09-30 using German routine healthcare data. Incidence rate differences (ΔIR) and ratios (IRR) of 96 potential PASC were estimated using Poisson regression. Analyses were stratified according to age (0-11, 12-17 years), and sex. At the individual level, persistence of diagnoses in patients with onset symptoms was tracked starting from the first quarter post-infection.

RESULTS:

At 0-3 month follow-up, children and adolescents with a previous SARS-CoV-2 infection showed a 34% increased risk of adverse health outcome, and approximately 6% suffered from PASC in association with COVID-19. The attributable risk was higher among adolescents (≥ 12 years) than among children. For most common symptoms, IRRs largely persisted at 9-12 month follow-up. IRR were highest for rare conditions strongly associated with COVID-19, particularly inflammatory conditions among children 0-11 years, and chronic fatigue and respiratory insufficiency among adolescents. Tracking of diagnoses at the individual level revealed similar rates in the decline of symptoms among COVID-19 and control cohorts, generally leaving less than 10% of the patients with persistent diagnoses after 12 months.

CONCLUSION:

Although very few patients presented symptoms for longer than 12 months, excess morbidity among children and, particularly, adolescents with a history of COVID-19 means a relevant burden for pediatric care.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article